INSUBCONTINENT EXCLUSIVE:
what she believes to be a better, cheaper, less painful test for endometriosis.Her company has just completed a Yale University -led
validation study and raised $10 million in Series A funding from CooperSurgical, TigerGlobal Management, Luxor Capital Group and the law
firm Wilson Sonsini Goodrich - Rosati to bring a new, non-invasive diagnostic test to market.Endometriosis is an often painful disorder in
The disease may affect up to one in 10 women of childbearing years and about half of all women who experience infertility, according to the
United States Department of Health and Human Services.However, even with clear symptoms of the disease, doctors often try to test for
endometriosis as a last resort
The only way currently to test for it is through an invasive laparoscopic procedure, which comes with risks like internal bleeding,
infections and hernia.Called DotEndo the new DotLab test eliminates that risk with a simple diagnostic test
also quick to point out DotEndo is not a genetic test, as there are plenty of testsouton the market helping women discover possible genetic
we definitely still have a long way to go in diagnosing and curing the disease and that will take a lot more capital from investors in the
future.Meanwhile, the next step for DotLab will be to get its test into the hands of physicians, with the hope they recommend DotEndo right
off the bat to patients exhibiting symptoms.
